Tomasz M. BeerM.D., F.A.C.P.

  • Deputy Director, OHSU Knight Cancer Institute; Chair; Grover C. Bagby Endowed Chair for Prostate Cancer Research
  • Professor of Medicine, Division of Hematology/Medical Oncology, School of Medicine

Expertise

  • Cancer

Special focus on

  • Prostate Cancer

I see patients at

Biography

Dr. Beer specializes in the medical care of prostate cancer patients. He has advanced training in oncology and has focused exclusively on prostate cancer during his entire career. He has authored or co-authored more than 250 peer reviewed articles on prostate cancer. Dr. Beer is particularly known for investigations of targeted therapies and immunotherapies in prostate cancer, including vitamin D receptor, the androgen receptor, CTLA-4 and PD-1 inhibitors, PSMA and others. He led the global randomized trial of enzalutamide vs placebo which demonstrated substantial improvements in overall and progression-free survival as well as quality of life and served as the basis for a global change in the standard of care for advanced prostate cancer. Dr. Beer offers expert advice to patients with all stages of prostate cancer, as well as a full range of medical treatments and access to clinical trials of new treatments.

Education

  • M.D., 1991, The Johns Hopkins University
  • Residency:

    • Oregon Health & Science University, Portland
  • Fellowship:

    • Hematology and Medical oncology, Oregon Health & Science University, Portland
  • Certifications:

    • Oncology

Languages

  • English
  • French
  • German
  • Polish
  • Russian (some)

Memberships and associations

  • American College of Physicians
  • Oregon Medical Association
  • American Society of Clinical Oncology
  • American Association for Cancer Research
  • Southwest Oncology Group
  • American Urological Association

Patient ratings

4.9 out of 5 (351 Ratings, 149 Comments)

The patient ratings score is an average of all responses to the question "How likely would you be to recommend this provider to your family and friends (on a scale of 0 to 10)" on our nationally-recognized NRC patient surveys.

  1. {{ item.comments[0]['comment'] }}